On the public citation graph

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)

https://doi.org/10.1177/1758835918807339
0 signed · 69 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cncr.11436openalex-snapshot
Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma
inferredcites →https://doi.org/10.1002/cncr.25771openalex-snapshot
Multifactorial central nervous system recurrence susceptibility in patients with HER2‐positive breast cancer
inferredcites →https://doi.org/10.1007/s00280-011-1653-5openalex-snapshot
Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer
inferredcites →https://doi.org/10.1007/s00280-013-2297-4openalex-snapshot
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528
inferredcites →https://doi.org/10.1007/s10549-015-3282-xopenalex-snapshot
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response
inferredcites →https://doi.org/10.1007/s10555-007-9077-8openalex-snapshot
Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis
inferredcites →https://doi.org/10.1007/s10637-011-9723-4openalex-snapshot
Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
inferredcites →https://doi.org/10.1007/s11060-011-0629-yopenalex-snapshot
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
inferredcites →https://doi.org/10.1016/j.cell.2004.12.040openalex-snapshot
The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation
inferredcites →https://doi.org/10.1016/j.ejca.2008.10.026openalex-snapshot
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
inferredcites →https://doi.org/10.1016/j.jnci.2014.08.001openalex-snapshot
All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer – A phase II study
inferredcites →https://doi.org/10.1016/s1470-2045(12)70432-1openalex-snapshot
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
inferredcites →https://doi.org/10.1016/s1470-2045(14)70138-xopenalex-snapshot
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
inferredcites →https://doi.org/10.1038/nm.4120openalex-snapshot
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases
inferredcites →https://doi.org/10.1038/sj.bjc.6605586openalex-snapshot
Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
inferredcites →https://doi.org/10.1056/nejm200103153441101openalex-snapshot
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
inferredcites →https://doi.org/10.1056/nejmoa052122openalex-snapshot
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa052306openalex-snapshot
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa0910383openalex-snapshot
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa1109653openalex-snapshot
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
inferredcites →https://doi.org/10.1093/neuonc/nou141openalex-snapshot
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study
inferredcites →https://doi.org/10.1097/00000421-198212000-00014openalex-snapshot
Toxicity and response criteria of the Eastern Cooperative Oncology Group
inferredcites →https://doi.org/10.1155/2013/234391openalex-snapshot
Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation
inferredcites →https://doi.org/10.1158/0008-5472.can-3554-2openalex-snapshot
Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells
inferredcites →https://doi.org/10.1158/1078-0432.ccr-04-2402openalex-snapshot
Dual Inhibition of mTOR and Estrogen Receptor SignalingIn vitroInduces Cell Death in Models of Breast Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-08-1080openalex-snapshot
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-18-3049openalex-snapshot
The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA -Mutant Breast Cancer Brain Metastases
inferredcites →https://doi.org/10.1159/000346844openalex-snapshot
Trastuzumab-Induced Hepatotoxicity: A Case Report
inferredcites →https://doi.org/10.1159/000353099openalex-snapshot
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
inferredcites →https://doi.org/10.1186/bcr3071openalex-snapshot
Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases
inferredcites →https://doi.org/10.1200/jco.19.00083openalex-snapshot
Neratinib Plus Capecitabine Provides a Glimmer of Hope for a Daunting Disease
inferredcites →https://doi.org/10.1200/jco.2005.04.173openalex-snapshot
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
inferredcites →https://doi.org/10.1200/jco.2005.05.249openalex-snapshot
Survival After Brain Metastases From Breast Cancer in the Trastuzumab Era
inferredcites →https://doi.org/10.1200/jco.2013.54.0955openalex-snapshot
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.1011openalex-snapshot
LCCC 1025: Phase II study of everolimus, trastuzumab, and vinorelbine for HER2+ breast cancer brain metastases (BCBM).
inferredcites →https://doi.org/10.1523/jneurosci.0955-08.2008openalex-snapshot
Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function
inferredcites →https://doi.org/10.5858/2007-131-18-asoccoopenalex-snapshot
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4147529openalex-extracted
Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1002/cam4.5021openalex-snapshot
Breast cancer brain metastasis: Current evidence and future directions
inferred← citeshttps://doi.org/10.1002/cam4.6180openalex-snapshot
Tyrosine kinase inhibitors in HER2 ‐positive breast cancer brain metastases: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/ijc.32937openalex-snapshot
Landscape of combination therapy trials in breast cancer brain metastasis
inferred← citeshttps://doi.org/10.1007/978-981-15-2361-8_7openalex-snapshot
Targeting the Key Signaling Pathways in Breast Cancer Treatment Using Natural Agents
inferred← citeshttps://doi.org/10.1007/s10549-019-05309-6openalex-snapshot
Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease
inferred← citeshttps://doi.org/10.1007/s11427-025-3311-5openalex-snapshot
HER2 targeted therapy resistance in breast cancer: from molecular landscape to clinical aspects
inferred← citeshttps://doi.org/10.1007/s12325-023-02538-6openalex-snapshot
Narrative Review of Multidisciplinary Management of Central Nervous Involvement in Patients with HER2-Positive Metastatic Breast Cancer: Focus on Elderly Patients
inferred← citeshttps://doi.org/10.1007/s40263-022-00975-5openalex-snapshot
Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
inferred← citeshttps://doi.org/10.1016/b978-3-437-21882-8.00012-8openalex-snapshot
Neuroonkologie
inferred← citeshttps://doi.org/10.1016/j.clbc.2020.11.014openalex-snapshot
Targeted Therapies for Breast Cancer Brain Metastases
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2021.103329openalex-snapshot
Current treatment options for HER2-positive breast cancer patients with brain metastases
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2022.103600openalex-snapshot
Global management of brain metastasis from renal cell carcinoma
inferred← citeshttps://doi.org/10.1039/d4bm00342jopenalex-snapshot
Matrix stiffness influences response to chemo and targeted therapy in brain metastatic breast cancer cells
inferred← citeshttps://doi.org/10.1093/brain/awae366openalex-snapshot
Bridging the gap: unlocking the potential of emerging drug therapies for brain metastasis
inferred← citeshttps://doi.org/10.1093/noajnl/vdaa136openalex-snapshot
HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-18-3049openalex-snapshot
The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA -Mutant Breast Cancer Brain Metastases
inferred← citeshttps://doi.org/10.1177/1533033820962140openalex-snapshot
Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
inferred← citeshttps://doi.org/10.1200/jco.19.00083openalex-snapshot
Neratinib Plus Capecitabine Provides a Glimmer of Hope for a Daunting Disease
inferred← citeshttps://doi.org/10.20517/cdr.2019.92openalex-snapshot
Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem
inferred← citeshttps://doi.org/10.26442/18151434.2019.2.190395openalex-snapshot
The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1801614openalex-snapshot
Breast cancer brain metastasis: from molecular insights to therapeutic innovation
inferred← citeshttps://doi.org/10.3389/fonc.2022.1086821openalex-snapshot
Systemic treatments for breast cancer brain metastasis
inferred← citeshttps://doi.org/10.3389/fphar.2020.01111openalex-snapshot
The Functional Role of Voltage-Gated Sodium Channel Nav1.5 in Metastatic Breast Cancer
inferred← citeshttps://doi.org/10.3390/cancers13164137openalex-snapshot
Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers
inferred← citeshttps://doi.org/10.3390/cancers14184543openalex-snapshot
Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs
inferred← citeshttps://doi.org/10.3390/cancers14205132openalex-snapshot
Anti-Hormonal Therapy in Breast Cancer and Its Effect on the Blood-Brain Barrier
inferred← citeshttps://doi.org/10.3390/cancers14205136openalex-snapshot
Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer
inferred← citeshttps://doi.org/10.3390/cancers14225612openalex-snapshot
Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.3390/ijms232012525openalex-snapshot
Advances in the Management of Central Nervous System Metastases from Breast Cancer
inferred← citeshttps://doi.org/10.3390/ijms252413376openalex-snapshot
The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review
inferred← citeshttps://doi.org/10.55976/dt.1202216523-36openalex-snapshot
Treatment of breast cancer brain metastases: radiotherapy and emerging preclinical approaches
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.